---
title: "Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296038998.md"
description: "Mesoblast Limited announced the completion of patient treatment in its pivotal Phase 3 trial (MSB-DR004) for rexlemestrocel-L, a therapy for chronic low back pain associated with degenerative disc disease. The trial randomized and treated 350 patients, exceeding the initial target of 300 due to strong investigator demand. The primary endpoint assesses durable pain reduction at 12 months. Top-line results are expected in mid-2027."
datetime: "2026-08-17T00:37:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296038998.md)
  - [en](https://longbridge.com/en/news/296038998.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296038998.md)
generator: "portal-rs"
---

# Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

On August 16, 2026, Mesoblast Limited, a leading global provider of allogeneic cellular medicines for inflammatory disorders, disclosed the completion of patient treatment in the MSB-DR004 Phase 3 trial. This trial focused on rexlemestrocel-L for chronic low back pain related to degenerative disc disease. The milestone was marked by treating 350 patients who were randomly assigned to receive either rexlemestrocel-L intra-discal injections or sham injections. Originally planned for 300 patients, the trial's capacity expanded due to high demand from investigators, resulting in an additional 50 patients being enrolled. Mesoblast Limited's stocks are listed on Nasdaq under MESO and ASX under MSB.

### Related Stocks

- [MESO.US](https://longbridge.com/en/quote/MESO.US.md)
- [MSB.AU](https://longbridge.com/en/quote/MSB.AU.md)

## Related News & Research

- [Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment](https://longbridge.com/en/news/296134582.md)
- [Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline](https://longbridge.com/en/news/294369651.md)
- [Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil](https://longbridge.com/en/news/283256521.md)
- [Bell Potter Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)](https://longbridge.com/en/news/284855691.md)
- [BUZZ-Australia's Mesoblast rises on FDA approval for new potency assay for commercial Ryoncil](https://longbridge.com/en/news/299956184.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**